Imatinib treatment in chronic myelogenous leukemia What have we learned so far?

被引：25
作者：
Breccia, Massimo [1 ]
Efficace, Fabio [2 ]
Alimena, Giuliana [1 ]
机构：
[1] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy
[2] Italian Grp Adult Hematol Dis GIMEMA, Hlth Outcome Res Unit, Ctr Data, Rome, Italy
来源：
CANCER LETTERS | 2011年 / 300卷 / 02期
关键词：
Chronic myelogenous leukemia; Imatinib; Compliance; CHRONIC MYELOID-LEUKEMIA; PATIENT COMPLIANCE; MEDICATION COMPLIANCE; ADHERENCE; THERAPY; PERSISTENCE; PHARMACOKINETICS; DETERMINANTS; MECHANISMS; MESYLATE;
D O I：
10.1016/j.canlet.2010.10.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Imatinib mesylate is currently the standard therapy for chronic myelogenous leukemia patients Despite the remarkable results achieved with imatinib the emergence of resistance to this drug has become a significant problem Actually two other second-generation tyrosine kinase inhibitors have been used for resistant/intolerant patients to imatinib With the availability of oral tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia questions relating to adherence to prescribed therapy have become an important issue It has been demonstrated that the effectiveness, of the treatment with imatinib requires high compliance to the prescribed dose of the drug for an indefinite period of time whereas reduced adherence to therapy has been associated with delay in achieving cytogenetic or molecular response and/or possible development of resistance The aim of this review is to discuss the Importance of adherence and the possible tools that we have to measure it to improve our knowledge on possible underlying causes of non-adherence and the Impact of non-adherence on hospitalization risk and healthcare cost through a systematic review of the data published to date (C) 2010 Elsevier Ireland Ltd All rights reserved
引用
收藏
页码：115 / 121
页数：7
相关论文
共 46 条
[1]   Same mutation, different allele [J].
Aichberger, Karl J. ;
Fleischman, Angela G. ;
Deininger, Michael W. .
BLOOD, 2009, 114 (14) :2853-2854
[2]  
Ailinger Rita L, 2008, Clin Nurs Res, V17, P89, DOI 10.1177/1054773808316941
[3]  
[Anonymous], ABSTRACT
[4]   Persistence of use of lipid-lowering medications - A cross-national study [J].
Avorn, J ;
Monette, J ;
Lacour, A ;
Bohn, RL ;
Monane, M ;
Mogun, H ;
LeLorier, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (18) :1458-1462
[5]   Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].
Baccarani, Michele ;
Cortes, Jorge ;
Pane, Fabrizio ;
Niederwieser, Dietger ;
Saglio, Giuseppe ;
Apperley, Jane ;
Cervantes, Francisco ;
Deininger, Michael ;
Gratwohl, Alois ;
Guilhot, Francois ;
Hochhaus, Andreas ;
Horowitz, Mary ;
Hughes, Timothy ;
Kantarjian, Hagop ;
Larson, Richard ;
Radich, Jerald ;
Simonsson, Bengt ;
Silver, Richard T. ;
Goldman, John ;
Hehlmann, Rudiger .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051
[6]   Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy [J].
Choo, PW ;
Rand, CS ;
Inui, TS ;
Lee, MLT ;
Cain, E ;
Cordeiro-Breault, M ;
Canning, C ;
Platt, R .
MEDICAL CARE, 1999, 37 (09) :846-857
[7]   INTENTIONAL PRESCRIPTION NON-ADHERENCE (NON-COMPLIANCE) BY THE ELDERLY [J].
COOPER, JK ;
LOVE, DW ;
RAFFOUL, PR .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1982, 30 (05) :329-333
[8]   Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia [J].
Cortes, J. E. ;
Egorin, M. J. ;
Guilhot, F. ;
Molimard, M. ;
Mahon, F-X .
LEUKEMIA, 2009, 23 (09) :1537-1544
[9]   Medication compliance and persistence: Terminology and definitions [J].
Cramer, Joyce A. ;
Roy, Anuja ;
Burrell, Anita ;
Fairchild, Carol J. ;
Fuldeore, Mahesh J. ;
Ollendorf, Daniel A. ;
Wong, Peter K. .
VALUE IN HEALTH, 2008, 11 (01) :44-47
[10]  
Darkow T, 2007, PHARMACOECONOMICS, V49, P22
12345